Results 81 to 90 of about 1,131 (155)

Molecular-Level Insights into the Reaction Mechanisms of Reductive Etherification for the Production of Synthetic Biofuels. [PDF]

ACS Omega
Doan HA, Li C, Miller JH, LiBretto NJ, Rein AL, Zhou M, Hafenstine GR, Vardon DR, Habas SE, Assary RS.   +9 more
europepmc   +1 more source

Selpercatinib in Chinese patients with <i>RET</i>-fusion-positive non-small-cell lung cancer: updated efficacy and safety analysis from the LIBRETTO-321 phase II trial. [PDF]

Ther Adv Med Oncol
Lu S, Cheng Y, Huang D, Sun Y, Wu L, Zhou C, Zhou J, Guo Y, Shao J, Zhang W.   +9 more
europepmc   +1 more source

Patient-Reported Outcomes From LIBRETTO-431: First-Line Selpercatinib Versus Chemotherapy With Pembrolizumab in <i>RET</i> Fusion-Positive NSCLC. [PDF]

JTO Clin Res Rep
Zhou C, Novello S, Garrido P, Dooms C, Alatorre-Alexander J, Reinmuth N, Worthy G, Cocks K, Williams J, Han H, Uh MK, Payakachat N, Gilligan AM, Goto K.   +13 more
europepmc   +1 more source

Targeting rare oncogenic mutations in resectable non-small cell lung cancer: emerging perioperative strategies. [PDF]

J Thorac Dis
Hao S, Zhao S, Shi L, Zhong L, Wei H, Jiao X, Xue C.   +6 more
europepmc   +1 more source

An emerging melody composed of the notes from structural variants - Comment on 'The fusion characteristics of RET fusion in pan-cancer among the Chinese population: A comprehensive genomic analysis' by Chen et al. [PDF]

Transl Oncol
Wu L, Zhou Q, Lu C.
europepmc   +1 more source

Investigating perceived stress and pain reduction following brief Reiki sessions in high-stress communities: an exploratory study. [PDF]

Front Psychol
McCutcheon H, Habiya SK.
europepmc   +1 more source

Selpercatinib for RET fusion-positive non-small cell lung cancer. [PDF]

Aust Prescr
europepmc   +1 more source

Acute severe hypocalcaemia after initiation of a selective RET-inhibitor in medullary thyroid cancer. [PDF]

Endocr Oncol
Cheng L, Ghaznavi SK, Stevens J, Hoy S, Wong KH, Malik T, Newbold K, Morganstein D.   +7 more
europepmc   +1 more source

Case Report: Complete pathologic response to neoadjuvant immunotherapy-chemotherapy in a patient with RET fusion-positive non-small cell lung cancer. [PDF]

Front Oncol
Wang Y, Zhang Y, Cai C, Liu X, Ren S, Zhou S.   +5 more
europepmc   +1 more source

The Utility of Tissue-Agnostic Drugs in Lung Cancer Treatment. [PDF]

Pharmaceut Med
Kong L, Grobman B, Mansur A, Lee A, Bondarchuk C, Erdogan H, Lu CY.   +6 more
europepmc   +1 more source